Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience  by Holmes, David R. et al.
668 JACC Vol. 26, No. 3 
September 1995:668-74 
Contemporary Reperfusion Therapy for Cardiogenic Shock: 
The GUSTO-I Trial Experience 
DAVID R. HOLMES, J~., MD, FACC, ERIC R. BATES, MD, FACC,* 
NEAL S. KLEIMAN, MD, FACC,~" ZYGMUNT SADOWSKI, MD,$ 
JOHN H. S. HORGAN,  MD, FACC,§ DOUGLAS C. MORRIS,  MD, FACC,II 
ROBERT M. CALIFF, MD, FACC,¶ PETER B. BERGER,  MD, FACC, 
ERIC J. TOPOL, MD, FACC,# FOk -I-HE GUSTO-I 1NVESIIGATORS 
Rochester, Minnesota: Ann Arbor. Mtchtgan; Houston, Iexas: Wur~aw, Poland; Dublin, Ireland; Atlanta, Georgia; 
Durham, North Carolina; and Clevelund, Ohto 
ObJectives. This study sought o examine the incidence, tempo- 
ral profile and clinical implications of shock in a large trial of 
thrombolytic therapy for acute myocardial infarction. 
Background. Despite advances in the treatment of acute isch- 
emic syndromes, cardiogenic shock remains associated with sig- 
nificant morbidity and mortality. 
Methods. Patients who presented within 6 h of symptom onset 
were randomized to four treatment strategies: 1) streptokinase 
plus subcutaneous heparin; 2) streptokinase plus intravenous 
heparin; 3) accelerated recombinant tissue-type lasminogen ac- 
tivator (rt-PA) plus intravenous heparin; or 4t streptokinase and 
rt-PA plus intravenous heparin. The primary end point was 
30-day all-cause mortality. 
Results. Shock occurred in 2,972 patients ~7.2%): 315 (11%) 
had shock on arrival, and 2,657 (89°/o) developed shock after 
hospital admission. Reinfarction occurred in 11% of patients who 
developed shock compared with 3% of patients without shock. The 
mortality rate was significantly higher in patients who presented 
with (57%) or developed (55%) shock than in those without shock 
(3%) (p < 0.001). Shock developed significantly less frequently in
patients receiving rt-PA. There were fewer deaths in patients who 
presented with shock and were treated with streptokinase plus 
intravenous heparin or who developed shock and were treated 
with streptokinase plus subcutaneous heparin. Patients who de- 
veloped shock had a significantly ower 30-day mortality rate if 
angioplasty was performed. 
Conclusions. Because cardiogenic shock occurred most often 
after admission and with recurrent ischemia nd reinfarction, 
recognizing signs of incipient shock may improve outcome. Fewer 
patients treated with rt-PA developed shock, yet those developing 
shock had the same high mortality rate as those presenting with 
shock, regardless of treatment. Only angioplasty was associated 
with a significantly ower mortality rate. 
(JAm CoU Cardiol 1995;26:668-74) 
Cardiogenic shock is a iclatively uncommon complication of 
acute myocardial infarctton, occurring in 5% to 15% of 
patients in published reports (1-5). The development of shock 
portends avery poor prognosis, and such patients account for 
a large proportion of the morbidity and mortality of acute 
infarction (1,2,4,6-10). Bctore the era of reperfusion therapy, 
the mortality rate from cardiogenic shock was -80%. In a 
recent longitudinal study of cardiogenic shock from 1975 to 
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1988 (2), the overall in-hospital case fatality rate was 77.7%. 
Over the course of the study, the short-term ortality rate 
actually worsened, increasing from 73.7% in 1975 to 81.7% in 
1988. 
Early reports of thrombolytic therapy documented a disap- 
pointing improvement i  mortality in patients with cardiogenic 
shock (8,11-16). In addition, many thrombolytie trials have 
systematically excluded patients with shock (17,18). In a recent 
meta-analysis of 94 reperfusion studies (19), only 22% in- 
cluded patients with cardiogenic shock, and only 3 studies 
performed subgroup analyses of patients with shock. Advances 
in reperfusion therapy have continued to occur with more 
widespread use of adjunctive therapies designed to maximize 
improvement in these high risk patients. The effect of these 
strategies on reducing mortality in patients with shock remains 
unclear. 
The multicenter Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded Coronary Arteries 
(GUSTO-I) trial (20) of 41,021 patients with acute myocardial 
infarction included aprospective plan for identifying the subset 
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of patients with cardiogenic shock. In the present report, we 
analyze the GUSTO-I experience with cardiogenic shock and 
define the incidence, temporal profile and 30-day outcome in 
patients undergoing contemporary eperfusion treatment. 
Methods  
Patients. The details and primary end points of the GUSTO-I 
trial have been previously reported (20). Patients with chest pain 
lasting ->20 rain but <6 h with typical electrocardiographic 
(ECG) abnormalities (>0.1-mV ST segment elevation in two 
or more limb leads or >0.2-mV ST segment elevation in two or 
more precordial leads) were eligible for randomization to one 
of four intravenous thrombolytic strategies: 1) streptokinase 
(Kabikinase, Kabi Vitmm, Stockholm, Sweden), 1.5 million U 
over 1 h, with subcutaneous heparin, 12,500 U twice daily 
beginning 4 h after streptoldnase; 2)streptokinase, 1.5 million U 
over I h with intravenous heparin (5,000-U bolus and infusion at 
1,000 U/h), adjusted to achieve an activated partial thromboplas- 
tin time of 60 to 85 s; 3) accelerated recombinant tissue-type 
plasminogen activator (rt-PA) (Activase, Genentech), 15-rag 
bolus, 0.75 mg/kg body weight over 30 rain (up to 50 rag) and 
0.5 mg/kg (up to 35 rag) over the next hour with intravenous 
heparin; or 4) combined rt-PA (1.0 mg/kg over 60 rain, not to 
exceed 90 rag, with 10% given as a bolus) and streptokinase 
(1 million U over 60 rain) with intravenous heparin. Patient 
exclusion criteria included previous stroke, active bleeding, 
allergy to streptokinase and recent rauma or major operation. 
Cardiogenic shock was not an exclusion criterion; patients with 
shock were prospectively identified as a subgroup that would 
be analyzed separately, and a special data collection form was 
designed and completed for all patients with shock. 
Adjunctive therapy included chewable aspirin, ->160 mg 
(Bayer), as soon as possible, followed by 160 to 325 rag/day. 
Unless contraindicated, intravenous atenolol, 10 mg (ICI 
Pharmaceuticals), was given in two divided doses followed by 
daily oral therapy of 50 to 100 nag. Other medications, includ- 
ing nitrates, angiotensin-converting e zyme inhibitors, digitalis 
and antiarrhythmic and calcium channel blocking agents, were 
used at the discretion of the attending physician. Angiography, 
percutaneous transluminal coronary angioplasty, intraaortic 
balloon pumping and coronary artery bypass graft surgery were 
also used at the discretion of the investigators. The primary 
end point of the trial was all-cause mortality at 30 days. Other 
end points included a composite of death and nonfatal, 
disabling stroke. 
Definitions. Cardiogenic shock was defined as systolic 
blood pressure <90 mm Hg for at least 1 h that was not 
responsive to fluid administration alone, thought o be second- 
ary to cardiac dysfunction and associated with signs of hypo- 
perfusion or a cardiac index -<2.2 liters/rain per m 2. Patients in 
whom systolic blood pressure increased to >90 mm Hg within 
1 h after administration of positive inotropic agents were still 
classified as having cardiogenic shock. Recurrent ischemia was 
defined as symptoms (chest discomfort, arm pain, jaw pain, 
nausea); ECG changes; and new hypotension, pulmonary 
edema or murmur thought by the physician to represent 
myocardial ischemia. When the physician determined that a 
second myocardial infarction had occurred, reinfarction was 
defined on the basis of the presence of two or more of the 
following criteria: 1) recurrent ischemic symptoms lasting 
>15 rain; 2) new ST-T wave changes or new Q waves; 3) a 
second elevation in cardiac enzyme levels to over the normal 
upper limit or by a further 20% if already over the normal 
upper limit; 4) angiographic reocclusion of a previously patent 
infarct-related artery. 
Data analysis and statistical assessment. Baseline charac- 
teristics and clinical outcomes of patients presenting with 
cardiogenic shock (group A), patients developing shock during 
the hospital period (group B) and patients without shock 
(group C) were compared using chi-square tests for discrete 
variables and the Wilcoxon rank-sum test for continuous 
characteristics. Odds ratios and 95% confidence intervals were 
used to compare treatments. Continuous data are summarized 
as mean value _+ SD. Results for categoric variables are given 
as the number and percent of patients with the specified 
characteristic. Significance tests were two-tailed, and treat- 
ments were compared using intention to treat. 
Resu l ts  
Patients. A total of 41,021 patients were enrolled. Cardio- 
genic shock was identified in 2,972 patients (7.2%), and data 
are missing for 285 patients. The majority of patients (2,657 
[89%]) developed shock after the initial admission to hospital, 
and only 315 patients (11%) had cardiogenic shock at their 
initial assessment. Figure 1 demonstrates the time to develop- 
ment of cardiogenic shock for the treatment groups by inten- 
tion to treat. The majority of patients who developed shock did 
so within 48 h of randomization. 
There were significant differences between patients without 
shock and the entire group of those with shock (Table 1). The 
latter had a significantly higher incidence of risk factors 
associated with an adverse outcome, including greater age, 
female gender, previous infarction, anterior myocardial infarc- 
tion and diabetes mellitus. As expected, systolic blood pressure 
was significantly lower and heart rate significantly higher in 
patients with cardiogenic shock. 
Thrombolytic therapy. There were differences in time to 
administration of thrombolytic therapy among the three 
groups. Patients who developed shock had a significantly 
longer time to therapy than patients without cardiogenic shock 
(3.20 _+ 1.75 h vs. 3.09 _+ 1.62 h, p -- 0.01). A similar proportion 
of patients were randomized to each treatment regimen; 
however, patients treated with accelerated rt-PA therapy were 
significantly less likely to develop cardiogenie shock than 
patients treated with the other regimens (Table 2) (p < 0.001). 
Procedures performed. The number and type of proce- 
dures performed, both diagnostic and therapeutic, differed 
greatly among the three groups (Table 3). The frequency of 
cardiac catheterization was significantly higher in the patients 
without shock, as was performance of balloon angioplasty. 
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Figure 1. Time to development of cardiogenic 
shock. Combination = streptokinase and re- 
combinant tissue-type lasminogen activator 
plus intravenous heparin; SK + SC = streptoki- 
nase plus subcutaneous heparin; SK + IV = 
streptokinase plus intravenous heparin; t-PA = 
accelerated recombinant tissue-type lasmino- 
gen activator. 
However, placement of an intraaortic balloon pump was 
significantly greater in patients with shock (22% and 25~ for 
those with shock on arrival and those who developed shock, 
respectively, vs. 2% for those who did not develop shock). As 
expected, the use of pacemakers, Swan-Ganz catheters and 
intubation for mechanical ventilation were all more frequent in 
patients with shock. Coronary' artery' bypass graft surgery was 
performed more frequently in patients who developed shock 
(12%) than in those without shock or in those who presented 
with shock (7%, p < 0.001). 
Complications and clinical events. In-hospital complica- 
tions were also significantly more frequent in patients with 
cardiogenic shock (Table 4), irrespective of when shock oc- 
curred. The most frequent arrhythmia was asystole, followed 
by ventricular fibrillation. 
The in-hospital and 30-day mortality rates were significantly 
different (Table 5). Of the 2,851 patients in the GUSTO-I trial 
who died at 30 days, 1,647 had had cardiogenic shock. There- 
fore, cardiogenic shock was present in 58% of all deaths at 30 
days in the entire trial. The 30-day mortality rates were 57~k 
and 55%, respectively, in patients with shock on arrival and 
those who developed shock during the hospital stay compared 
with only 3% in patients with no shock. The combined end 
point of death or nonfatal, disabling stroke was similarly 
increased (59% and 56% vs. 4%, respectively). Patients who 
developed cardiogenic shock during the hospital stay had 
markedly increased rates of reinfarction and recurrent isch- 
emia: Reinfarction occurred in 11% compared with 3% in 
patients with no shock (p < 0.001), and recurrent ischemia 
occurred in 28% and 19%, respectively (p < 0.001). 
With respect o the four different hrombolytic strategies, 
there were nonsignificant differences in major clinical events 
(Table 6, Fig. 2). In patients with shock on arrival, those given 
streptokinase and intravenous heparin tended to have a lower 
in-hospital and 30-day mortality rate and combined end point 
of 30-day mortality or nonfatal, disabling stroke. In the larger 
group of patients who developed shock during the initial 
hospital stay, the streptokinase and subcutaneous heparin 
strategy was associated with a lower mortality rate (51% vs. 
57% for rt-PA at 30 days) and combined end point of mortality 
or nonfatal, disabling stroke (52% vs. 57% for rt-PA). 
Performance of balloon angioplasty. There was a relation 
between performance of dilation and outcome in the patients 
with shock (Table 7). Although angioplasty was performed in 
only a minority of patients in GUSTO-I (22%), there was a 
statistically significant and clinically important difference in 
patients with shock. The 30-day mortality rate in patients with 
cardiogenic shock on arrival who underwent angioplasty was 
43% compared with 61% (p = 0.028) in patients with shock on 
arrival who did not undergo this procedure. Even more striking 
were the results of angioplasty in the larger group of patients 
who developed shock during the hospital stay. When angio- 
plasty was performed in this group, the 30-day mortality rate 
was 32% versus 61% in patients who did not undergo dilation 
(p < 0.001). 
Discuss ion  
Results of clinical trials. The GUSTO-I trial, a large 
multicenter randomized trial of thrombolytic therapy for acute 
myocardial infarction, documented that cardiogenic shock 
remains an extremely serious complication. Death in associa- 
tion with cardiogenic shock accounted for 58% of all deaths in 
this 41,021-patient trial. The overall 30-day mortality rate in 
patients with cardiogenic shock was 55%. In this series, the 
paradox exists that, whereas cardiogenic shock is less common 
in patients treated with accelerated rt-PA, rt-PA appears to be 
less effective in the setting of shock that is present on arrival. 
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Table 1. Baseline Clinical Characteristics 
Shock on Developed 
Arrival Shock No Shock 
(n = 315) (n = 2,657) (n = 37,746) 
Age (yr) 66.3 _+ 10.7 67.1 _+ 11.2 60.4 ,+ 11.8' 
Male gender (%) 63 63 76 
Hypertension (%) 39 44 38 
Diabetes (%) 23 18 14 
Previous MI (%) 28 25 16 
Previous bypass urgery (%) 5 7 4 
Infarction location (%) 
Anterior 54 50 38 
Inferior 42 47 58 
Other 4 3 3 
Kil[ip class (%) 
I 0 70 87 
II 0 24 12 
III 0 6 1 
IV 100 0 0 
Time to therapy (h) 2.97 -+ 1.47 3.20 _+ 1.75 3.09 _+ 1.62] 
Systolic BP (mm Hg) 94.1 _+ 28.2 117.7 ,+ 25.6 130.1 _+ 22.7 
Heart rate (beats/rain) 88.8 _+ 30.7 81.4 + 20.7 74.9 ,+ 17.0 
Treatment randomization (%) 
SK + SC heparin 23 27 24 
SK + IV heparin 25 27 25 
rt-PA + IV heparin 25 22 26 
Combination therapy 27 24 25 
*All p < 0.001, unless otherwise indicated, for any shock versus no shock. 
?p = 0.02 for any shock versus no shock. Data presented are percent of patients 
or mean value -+ SD. BP = blood pressure; Combination therapy = streptoki- 
nase (SK) and recombinant tissue-type plasminogen activator (rt-PA) plus 
intravenous (IV) heparin; MI = myocardial infarction; SC = subcutaneous. 
Although angioplasty was used in only a minority of patients, it
was associated with improved outcome. 
Information from clinical trials of thrombolytic therapy and 
cardiogenic shock has been limited (8,19). In many thrombo- 
lyric trials, cardiogenic shock has been a specific exclusion 
criterion. In a recta-analysis of94 randomized clinical trials of 
thrombolytic therapy through 1991 (19), only 3 performed 
subgroup analyses of patients with cardiogenic shock on ar- 
rival. Two of these three trials, which in aggregate included 636 
patients, compared thrombolytic therapy with a control group; 
both failed to demonstrate a benefit in terms of reduced 
in-hospital mortality (11,16,19). Two other placebo-controlled 
trials documented 25% and 43% reductions inthe incidence of 
Table 2. Incidence of Shock for Each Assigned Therapy 
rt-PA SK + IV Combination SK + SC 
(n = 10,376) (n = 10,393) (n = 10,346) (n = 9,820) 
Arrived in shock 0.8 0.8 0.8 0.7 
Developed 5.5 6.9 6.3 7.4 
shock* 
No shock* 93.7 92.4 92.9 91.8 
*p < 0.001 for patients who developed shock versus those who did not and 
for rt-PA versus other thrombolytic agents. Data presented are percent of 
patients. Abbreviations as in Table 1. 
Table 3. Procedures Performed 
Shock on Developed 
Arrival Shock No Shock 
(n = 315) (n - 2,657) (n = 37,764) 
Cardiac catheterization 123 (40) 1,228 (46) 21,201 (56)* 
PTCA 48 (15) 519 (20) 8,305 (22) 
Intraaortic balloon 68 (22) 666 (25) 745 (2) 
Bypass urgery 23 (7) 317 (12) 3,161 (8) 
Cardioversion/defibrillation 113 (37) 928 (35) 2,763 (7) 
Intubation 176 (56) 1,250 (47) 3,217 (9) 
Swan-Ganz catheter 127 (41) 1,183 (45) 3,720 (10) 
Pacemaker insertion 79 (25) 721 (27) 2,054 (5) 
*All p < 0.001 for any shock versus no shock. Data presented are number 
(%) of patients. PTCA = percutaneous transluminal coronary angioplasty. 
cardiogenic shock after thrombolytic treatment compared with 
placebo, although when shock developed, mortality remained 
substantially increased (17,18). 
The International Study Group (21) documented lower 
mortality in patients with shock treated with streptokinase than 
in those treated with rt-PA. In that study, 64.9% of the patients 
treated with streptokinase died compared with 78.1% of the 
rt-PA-treated patients (p = 0.04). A trend toward improved 
mortality with streptokinase was also found in the present 
study, where patients who developed shock and who had been 
treated with streptokinase and subcutaneous heparin had a 
30-day mortality of 51% compared with 57% for patients 
treated with rt-PA (p -- 0.061). The mechanism for this 
reduction is not clear. Other possible explanations include 
afterload reduction related to hypotension with streptokinase 
(which would not seem beneficial in this setting) or decreased 
viscosity and attendant improved microcirculatory flow. Alter- 
natively, these results could have occurred by chance; however, 
the fact that the same trend was present in another study 
makes this less likely. Although there was a trend toward 
improved mortality with streptokinase once shock developed, 
shock subsequently developed less frequently in patients ran- 
domized to rt-PA than streptokinase. This may be the result of 
the improved initial reperfusion rates with rt-PA. For preven- 
tion of shock, therefore, rt-PA is the preferred strategy. 
Table 4. In-Hospital Complications 
Shock on Developed 
Arrival Shock No Shock 
(n = 315) (n = 2,657) (n = 37,764) 
AV block 78 (25) 751 (28) 2,530 (7)* 
Asystole 129 (42) 1,062 (40) 1,130 (3)* 
Sustained VT 87 (28) 693 (26) 1,724 (5)* 
Ventricular fibrillation 100 (32) 687 (26) 1,930 (5)* 
Acute mitral regurgitation 12 (4) 176 (7) 383 (1) 
Ventricular septal defect 3 (1) 65 (2) 127 (0.3) 
*p < 0.001 for any shock versus no shock. Data presented are number (%) 
of patients (patients who developed multiple complications are counted more 
than once; therefore, the percent of patients may exceed 100). AV = atrioven- 
tricular; VT = ventricular tachycardia. 
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Table 5. Clinical Events 
Shock on Developed 
Arrival Shock No Shock 
(n - 315) {n - 2,657) (n - 37,764t 
Reinfarction 5 (2} 302 (11) 1,312 (3)* 
Recurrent ischemia 35 (11 i 740 (28) 7,323 (19):' 
Mortality 
In-hospital 181 (57) 1,477 (56) l,lll9 (3)* 
30-day 181 (57) 1.486 (55)¢ 1,164 (31' 
Stroke 8 (3) 72 (3) 510 (1) 
Hemorrhagic I (0.31 23 (11.9) 242 (ll.~) 
Nonhemorrhagie 5 (2.Ill 33 (1.0) 3210. I) 
30-day mortality or nonfatal. 186 (59) 1,496 (56) 1,477 (4)* 
disabling stroke 
*p < 0.001 for any shock versus no yhock. +Value is lower than that ol 
in-hospital mortality because 11 patients died in hospital after stays >30 days. 
Data presented are number (~;i) of patients 
Timing of shock. The temporal profile of cardiogenic 
shock in patients with acute myocardial infarction is of sub- 
stantial interest in view of the high mortaliW rate. In the 
present study, only a minority of patients presented with 
cardiogenic shock on admission; 89¢~ developed shock after 
admission, the majority during the first 48 h after randomiza- 
tion. Other studies have documented similar findings (15). The 
preponderance of shock developing during the hospital stay 
may be a consequence of excluding patients presenting with 
shock from enrollment in clinical trials. Col el al. (19) have 
suggested that this may relate to ditficul~ in obtaining in- 
formed consent in this high risk population, urgency in treating 
them versus taking time for randomization protocols or physi- 
cian perception of the appropriateness of the specific approach 
in these patients. 
In the GUSTO-I trial, patients who developed cardiogenic 
shock were more likely to have reinfarction. Whether these 
patients had a larger index infarction or developed infarct 
extension cannot be determined. 
Characteristics of patients who developed shock. Other 
studies with smaller patient numbers have documented factors 
associated with development of shock. The Secondary Preven- 
tion Reinfarction Israeli Nifedipinc Trial (SPRINT) study 
group (15) identified several factors that were independent 
predictors of shock, including increasing age, female gender. 
history, of angina pectoris, history of stroke, peripheral vascular 
disease, peak lactate dehydrogenase levels and hyperglycemia. 
Patients who had all factors, excluding lactate dehydrogenase 
elevation, had a 35% probability of developing in-hospital 
shock. The predictive value in a large population of patients 
remains to be determined. 
The extent of myocardial loss required for the development 
of cardiogenic shock is thought o be at least 40% (22,23). 
These data are based on autopsy series; more recent nuclear 
scintigraphy using technetium-99m sestamibi (24) has shown 
that some patients with >40% infarction of the left ventricle 
may survive without congestive heart failure. Certainly larger 
infarctions have the greater propensity toward shock unless a 
specific mechanical factor is the etiology (e.g., ventricular 
septal defect or mitral regurgitation). Identification of patients 
with recurrent ischemia or recurrent infarction should alert the 
clinician to an increased potential for the development of 
cardiogenic shock. 
A central finding of the present study is that the patients 
who developed cardiogenic shock during the hospital stay, 
under medical treatment, had the same high mortality as those 
with shock on arrival. This finding underlines the importance 
of developing algorithms for identification of high risk patients 
so that preventive strategies can be undertaken. 
Adjunctive therapies. Despite the finding that mortality in 
GUSTO-I patients treated with thrombolytic therapy appeared 
to improve compared with that of historical cohorts, it re- 
mained very high. Thera W to interrupt he process of infarct 
extension or the natural progression of large infarcts during 
shock is currently being evaluated, including adenosine, L- 
carnitine, Rheothrix, P selectin inhibitors and fructose diphos- 
phate (25-27). 
Other adjunctive therapy has focused on restoration of 
patency in the infarct-related artery. In addition to infarct size, 
patency of the infarct-related artery is one of the most impor- 
tant predictors of in-hospital mortality. In a series of 200 
patients with cardiogenic shock (6), the mortality of patients 
with a patent infarct-related artery was 33% versus 75% in 
those with an occluded artery. In selected series, the use of 
balloon angioplasty appears to be associated with improved 
outcome (28-33). Although angioplasty was performed in only 
19% of GUSTO-I patients with shock, those who developed 
Table 6. Outcome by Treatment Received 
P 
Outcome rt-PA SK + [V Combination SK + SC Value 
Shock on arrival (n - 315) 
In-hospital mortality, 47 (59) 43 (54) 50 (60) 41 (57) 0.82 
30-day mortality 49 (6l) 43 (54) 48 (57) 41 (59) 0.85 
30-day mortality or nonfatal, disabling stroke 49 (61) 44 (56) 52 (62) 41 (57) 0.92 
Developed shock (n 2,657) 
In-hospital mortality 326 (57) 404 (57) 371 (57) 376 (52) 0.10 
30-day mortality 323 (57) 399 (56) 37(I (57) 374 (51) 0.12 
30-day mortality or nonfatal, disabling stroke 325 (57) 404 (57) 375 (58) 380 (52) 0.15 
Data are number (%) of patients. Abbreviations as in Table 1. 
JACC Vol. 26, No. 3 HOLMES ET AL. 673 
September 1995:668-74 CARDIOGENIC SHOCK IN GUSTO-I 
Arriving in shock (n=315) 
In-hospital mortality (n=181) 
30-day mortality (11=181} 
30-day mortality or 11onfatal, 
disabling stroke (n=186) 
Developed shock (n=2657) 
In-hospital mortality (!m,1477) 
30-day mortality (n=1466) 
30-day mortality or nonfatal, 
disabling stroke (n=1496) 
O 
t-PA better 
I I " 
t _. I 
I I 
0.5 1.0 1.5 2.0 2.5 
Other therapy better 
Figure 2. Odds ratios: outcomes according totreatment 
received, t-PA = recombinant tissue-type lasminogen 
activator. Squares = odds of end point occurring in 
individual patients; horizontal bars = 95% confidence 
interval. 
shock during the hospital stay and underwent dilation had a 
mortality rate of 31% compared with 61% for patients who did 
not. These findings must be interpreted cautiously because of 
the potential risk of confounding in this analysis: Patient 
selection criteria for angiography and dilation, in addition to 
actual treatment received, could have had a major impact on 
the observed outcomes. Hochman et al. (10), in a pilot study of 
cardiogenic shock, documented that patients who underwent 
angiography had an improved outcome compared with pa- 
tients who did not, irrespective of whether they had angio- 
plasty. The most plausible hypothesis that patients who are 
too ill to undergo angiography are at increased risk for a fatal 
outcome; these patients would have been counted in the "no 
angioplasty" group, leading to a substantial bias. The same 
considerations apply for the finding in the present study of 
improved outcomes in patients who underwent dilation. Pa- 
tients who are at very high risk may not survive long enough to 
undergo angioplasty. However, because of the important rela- 
tion between patency and improved left ventricular function 
and survival in the GUSTO-I angiographic substudy, it is 
reasonable tomaximize reperfusion i these high risk patients. 
Other adjunctive therapies are also important (34-40). 
Intraaortic balloon counterpulsation has been shown to en- 
hance lysis and perfusion and to prevent reocclusion (35-40). 
It has also recently been shown to improve the outcome in 
patients with cardiogenic shock (40). In view of the available 
data, intraaortic balloon pumping may have been underutilized 
in the GUSTO-I trial because it was used in only 22% of 
patients with shock on arrival and in 25% of patients who 
developed shock during the hospital stay. However, many 
Table 7. Relation Between Procedure and Outcome 
30-Day Mortality 
P 
Cath Only PTCA CABG None Value 
Shock on arrival 10 (20) 20 (43) 5 (22) 143 (77) < 0.001 
Developed shock 160 (35) 145 (32) 93 (29) 1,057 (75) < 0.001 
No shock 119 (1) 62 (1) 45 (1) 934 (6) < 0.00l 
Data presented are number (%) of patients. CABG coronary artery'bypass 
graft surgery; Cath = catheterization; PTCA - percutaneous transluminal 
coronary angioplasty. 
centers did not have on-site facilities for placement of a 
balloon pump. The combination of mechanical reperfusion 
and intraaortic balloon pumping may optimize outcome. Fi- 
nally, surgical revascularization may also play a role, although 
the logistics are daunting and mortality is high. 
Conclusions. Cardiogenic shock in association with acute 
myocardial infarction resulted in markedly increased mortality 
and was present in a majority of the patients in the GUSTO-I 
trial who died. This high mortality was seen whether the 
patient presented with or developed shock. The rt-PA treat- 
ment was associated with a reduction in the subsequent 
development of cardiogenic shock compared with streptoki- 
nase; however, if shock was present on arrival, patients ran- 
domized to streptokinase t nded to have improved survival. 
Streptokinase treatment was associated with a somewhat lower 
mortality, probably related to its relative lack of dependency 
on tissue perfusion for clot lysis. However, irrespective of the 
specific thrombolytic regimen used, the mortality rates for 
patients with shock remained very high. Most commonly, shock 
occurred after admission and in the setting of recurrent 
ischemia or reinfarction. Patients with cardiogenic shock who 
underwent dilation showed substantial improvement in sur- 
vival compared with those who did not. These data support an 
intense effort at recognizing patients at risk for shock and an 
aggressive approach to reperfusion i these high risk patients. 
Patients who developed shock during the hospital stay had the 
same prognosis as those with shock on arrival. Development of 
a means of recognizing incipient signs of shock may lead to 
methods of further enhancing outcomes. 
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